BCM
ZNTL icon

Boxer Capital Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Boxer Capital Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-450,000
Closed -$1.36M – 59
2024
Q4 		$1.36M Buy
+450,000
New +$1.47M 0.12% 51

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Boxer Capital Management's ZNTL Position: Q1 2025 in Review

Boxer Capital Management sold out of Zentalis Pharmaceuticals (ZNTL) in Q1 2025, closing a stake of 450,000 shares — an estimated $1.36M sold.

Boxer Capital Management first reported a position in ZNTL in Q4 2024 and held it in 1 quarter. The position peaked at $1.36M in Q4 2024. 132 funds tracked by Wall St. Rank hold ZNTL as of Q1 2025.

  • Boxer Capital Management reported no remaining Zentalis Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Boxer Capital Management sold 450,000 Zentalis Pharmaceuticals shares in Q1 2025, an estimated $1.36M.
  • Boxer Capital Management first reported a position in Zentalis Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Boxer Capital Management's Zentalis Pharmaceuticals position peaked at $1.36M in Q4 2024.
  • 132 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2025.

Based on Boxer Capital Management's 13F filing for Q1 2025, filed 15 May 2025.